

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re the application of: Andrew Shyjan

Serial No: 09/528,031

Filed: March 17, 2000

For: *Novel Multidrug Resistance-Associated  
Polypeptide*

Attorney Docket No: MNI-056CPCN

Group Art Unit:

Examiner:

RECEIVED

JUL 26 2001

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231  
BOX Sequence

# 4B  
KD  
7-25-21


Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on the date set forth below.

July 20, 2000

Date of Signature and of Mail Deposit

By:

  
Debra J. Milasinec  
Registration No. 46,931  
Attorney for Applicant

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Dear Sir:

Responsive to the Notice to Comply with Requirements for Patent Applications Containing Sequence Disclosures dated June 20, 2001, Applicants' attorney submits the following remarks.

**REMARKS**

When transmitting the instant application to the U.S. Patent and Trademark Office, Applicants stated, pursuant to 37 CFR 1.821(e), that the computer readable form